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Polycyclic aromatic hydrocarbons (PAHs) are
found at a variety of contaminated sites
throughout the world from industries such as
coal gasiﬁcation, coke production, aluminum
production, iron and steel foundries, and creo-
sote and asphalt production. Some PAHs, for
example, the well-studied benzo(a)pyrene
(BaP), are mutagenic and carcinogenic in
experimental animals and probably in humans
also [Boffetta et al. 1997; International Agency
for Research on Cancer (IARC) 1987; Rubin
2001]. Therefore, health risk assessment of
PAHs with a view to setting acceptable levels
in contaminated soil is an important challenge
for regulatory toxicologists.
Various methods are employed by agencies
to estimate the risk posed by a certain level of
soil contaminant, all of which have advantages
and disadvantages. Threshold methods seek to
determine a threshold below which no adverse
effects are expected and that yield values such
as the tolerable daily intake (TDI) or reference
dose (RfD). These methods have the dis-
advantage that they hinge upon the no
observed adverse effect level (NOAEL), which
must be one of the chosen exposure levels in a
toxicologic study. This exposure level is
unlikely to be the actual threshold no effect
level. For setting guideline levels based on
cancer risk, the linearized multistage (LMS)
model is used by the U.S. Environmental
Protection Agency (EPA); this model assumes
that the dose–response curve is linear in the
low-dose region of the curve and that no
threshold exists. This assumption has the dis-
advantages of not taking into account the
complexities of the carcinogenic process and
of not accommodating the possibility that the
dose–response data may be best explained by
a curve that is nonlinear in the low-dose
region. In addition, the LMS approach
requires a societal judgment on what consti-
tutes an “acceptable” level of risk. Use of the
LMS method results in the most conservative
regulatory guidelines.
An alternative approach to the prepara-
tion of regulatory guidelines is the benchmark
dose (BMD) method to model toxicologic
end points. This method uses conventional
mathematical models to obtain dose–response
curves; that is, it does not assume linearity in
the low-dose region. The BMD approach has
been developed particularly by Crump (1984,
1995) and the U.S. EPA (1995). The current
U.S. EPA default approach is to calculate the
95% lower conﬁdence limit on a dose associ-
ated with a 10% extra tumor risk level (U.S.
EPA 2003). However, the disadvantage of
this method is that it applies a statistically
derived 95% lower confidence limit on the
dose–response curve that may not be valid
for the small data sets often encountered in
toxicology studies.
The National Health and Medical
Research Council (NHMRC) of Australia
embarked on a project to identify a cancer risk
assessment process that avoided the extreme
conservatism inherent in the assumption of
low-dose linearity but that used any available
dose–response data. The NHMRC Technical
Working Party on Carcinogenic Risk
Assessment for Soil Contaminants developed
the modiﬁed BMD method (NHMRC 1999).
This approach combines toxicologic dose–
response data (usually from animal studies)
and conventional mathematical models to
generate dose–response curves for the chemi-
cal in question, even in the subexperimental
region, and does not assume a linear relation-
ship in this region. The approach avoids the
conservatism of other BMD models by relying
on best-fit modeling rather than 95% lower
confidence limits on dose. For the various
models applied, the technique determines an
average dose at which 5% extra risk is incurred
(BMD0.05); this level of risk was chosen
because it is near the lower limit of responses
that can be experimentally measured.
Modifying factors reflecting the degree of
uncertainty in extrapolating from animal expo-
sure are then applied to yield a guideline dose
for human exposure.
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Assessment of cancer risk from exposure to polycyclic aromatic hydrocarbons (PAHs) has been
traditionally conducted by applying the conservative linearized multistage (LMS) model to animal
tumor data for benzo(a)pyrene (BaP), considered the most potent carcinogen in PAH mixtures.
Because it has been argued that LMS use of 95% lower conﬁdence limits on dose is unnecessarily
conservative, that assumptions of low-dose linearity to zero in the dose response imply clear
mechanistic understanding, and that “acceptable” cancer risk rests on a policy decision, an alterna-
tive cancer risk assessment approach has been developed. Based in part on the emerging bench-
mark dose (BMD) method, the modified BMD method we used involves applying a suite of
conventional mathematical models to tumor dose–response data. This permits derivation of the
average dose corresponding to 5% extra tumor incidence (BMD0.05) to which a number of modi-
fying factors are applied to achieve a guideline dose, that is, a daily dose considered safe for human
lifetime exposure. Application of the modified BMD method to recent forestomach tumor data
from BaP ingestion studies in mice suggests a guideline dose of 0.08 µg/kg/day. Based on this and
an understanding of dietary BaP, and considering that BaP is a common contaminant in soil and
therefore poses human health risk via soil ingestion, we propose a BaP soil guideline value of
5 ppm (milligrams per kilogram). Mouse tumor data from ingestion of coal tar mixtures contain-
ing PAHs and BaP show that lung and not forestomach tumors are most prevalent and that BaP
content cannot explain the lung tumors. This calls into question the common use of toxicity equiv-
alence factors based on BaP for assessing risk from complex PAH mixtures. Emerging data point to
another PAH compound—7H-benzo(c)fluorene—as the possible lung tumorigen. Key words:
benzo(a)pyrene, cancer risk assessment, dose–response modeling, modified benchmark dose
method, PAH, 7H-benzo(c)fluorene, soil carcinogens. Environ Health Perspect 112:1341–1346
(2004). doi:10.1289/ehp.6427 available via http://dx.doi.org/ [Online 15 July 2004]
Research ArticleThe purpose of this study was to use the
modified BMD method to construct tumor
dose–response curves for BaP using data from
a recently published 2-year feeding study on
female B6C3F1 mice (Culp et al. 1998).
Previous rodent BaP feeding studies were also
evaluated but either lacked sufficient data
points or exposure times (Brune et al. 1981;
Neal and Rigdon 1967) or suggested lesser sen-
sitivity (Kroese et al. 2001). We used the BMD
obtained from the Culp et al. (1998) data set
to calculate a guideline value for BaP in soil.
The recent BaP bioassay (Culp et al. 1998)
also examined the tumor response of female
B6C3F1 mice to two coal tar mixtures.
Although data generated would be reasonably
assumed to be useful in assessing risk from
exposure to complex mixtures, such data
reveal some unresolved issues. These relate
primarily to the difficulties of the simplistic
BaP-equivalence approach of PAH additivity
in the mixture, and the emerging notion that
perhaps a PAH other than BaP ought to be
the risk driver in these mixtures. This is fur-
ther discussed in the present article.
In conducting this exercise, it has been nec-
essary to adhere to the process set out in the
nationally developed modiﬁed BMD method
document (NHMRC 1999). However, as with
any emerging field, refinements will be pro-
posed over time that will decrease uncertainties
in this risk assessment approach.
Materials and Methods
Dose calculation. Culp et al. (1998) reported
their dose data as dietary concentrations. To
permit us to convert dietary concentrations to
average daily doses on a body weight basis,
S. Culp (National Center for Toxicological
Research, Jefferson, AR, USA) provided
information on the average amount of food
consumed per animal per day and the average
animal body weights. We calculated average
doses in units of milligrams per kilogram per
day for each of the 12 dose groups every
4 weeks until the end of the study, or until all
animals were removed from the study in a par-
ticular dose group. These doses were then aver-
aged to obtain an “average lifetime dose” for
each group, as presented in Table 1. The doses
for the coal tar mixtures are also given in BaP
equivalents for comparison purposes. These
BaP equivalents were calculated using previ-
ously published toxicity equivalence factors
(TEFs) for PAH mixtures (Fitzgerald 1998).
Culp et al. (1998) reported results for
several types of tumors induced by BaP and
two coal tar mixtures. For BaP, forestomach
tumors proved to be the most sensitive end
point (Table 1), and these dose–response data
are used here to determine a guideline value.
In the case of the coal tar mixtures, lung
tumors were shown to be the most sensitive
end point (Table 1).
Mathematical modeling. The NHMRC
Technical Working Party document on the
modified BMD method (NHMRC 1999)
requires the construction of dose–response
curves by fitting dose–response data with a
suite of mathematical models. A suite is used
to overcome bias when using a single model
that is attempting to simulate an underlying
but unknown model. The models are para-
metric and are the cumulative probability dis-
tribution functions (cdfs) for the well-known
Weibull, log normal (probit), log logistic,
gamma (multi-hit), and linear exponential
(single hit) distributions as well as the trun-
cated logistic and truncated normal distribu-
tions. The NHMRC recommends use of the
Weibull, probit, and linear exponential models
as a default selection with the option of an
expanded or alternative selection of models.
The expanded set of seven models has three
parameters to be found from the data (except
for the linear exponential, with two) and
includes the zero dose background response.
We chose three-parameter models for parsi-
mony and because data sets for carcinogens
often consist of just three or four data points.
Dose–extra-risk curves are determined by
transformation of dose–response curves in the
following way. If the cdfs are represented by
P*(d) for a dose d, such that P*(d) ranges from
0 at d = 0 to 1 for a very high dose, then the
fitted models all have the form P(d)=
c +( 1–c)P*(d), where c is the background
response. Extra risk is then defined by R =
[P(d)–P(0)] ÷ [(1 – P(0)] = P*(d). At R = 5%,
the BMD0.05 for a particular model is that
value of d such that P*(d) = 0.05. This value is
then determined for each model. Results from
any particular curve are discarded only if it is
clear that the model does not fit. The
NHMRC procedure (NHMRC 1999) uses
the BMD0.05 as determined by each acceptable
model and then arithmetically averages them.
The details of calculation of the BMD0.05
using the maximum likelihood estimate (MLE)
for ﬁtting cdf values to the data are provided in
the Supplemental Material available online
(http://ehp.niehs.nih.gov/members/
2004/6427/supplemental.pdf).
Modifying factors. To develop the guideline
value from the BMD0.05 requires dividing the
BMD0.05 by a modifying factor that takes into
account interspecies extrapolation, intraspecies
variability, the quality of the data set as a
whole, the ability of the compound to induce
malignant tumors, and the genotoxicity of the
compound in question (NHMRC 1999).
Modifying factors for BaP. Table 2 lists
the modifying factors established for BaP, the
numerical range of the factors, and the fac-
tors proposed for use in this guideline value
development. The development of modifying
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Table 1. Doses for coal tar mixtures and BaP administered for 2 years in the diet of B6C3F1 mice,a and tumorigenic responses in forestomach and lung.
Concentration Average lifetime dose BaP equivalent dose Actual BaP dose Mice with tumors/total mice
Dose group in diet (ppm) (mg/kg/day)b (mg/kg/day)c (mg/kg/day) Forestomachd Lunge
Coal 0 0 0 0 0/47 2/47
Tar 100 12.4 0.051 0.023 2/47 3/48
Mix 1 300 35.8 0.15 0.066 6/45 4/48
1,000 121 0.49 0.222 3/47 4/48
3,000 367 1.46 0.675 14/46 27/47
6,000f 707 2.92 1.299 15/45 25/47
10,000f 1,234 5.01 2.268 6/41 21/47
Coal 0 0 0 0 0/47 2/47
Tar 300 36.4 0.21 0.100 3/47 4/48
Mix 2 1,000 124 0.72 0.342 2/47 10/48
3,000 339 1.97 0.936 13/44 23/47
BaP 0 0 1/48 5/49
5 0.65 3/47 0/48
25 3.5 36/46 4/45
100f 15.3 46/47 0/48
aDetails from Culp et al. (1998) and S.J. Culp (personal communication); dose groups included zero dose controls, and animals in all groups were dosed for 2 years from 5 weeks of age.
bFrom animal weight and food intake data, averaged over the study period (Culp SJ, personal communication). cFrom PAH levels in Culp et al. (1998) and from TEFs in Fitzgerald [1998;
BaP, 1; dibenz(a,h)anthracene, 4; benz(a)anthracene, 0.1; benzo(b)ﬂuoranthene, 0.1; benzo(k)ﬂuoranthene, 0.1; indeno[1,2,3-c,d]pyrene, 0.1; anthracene, 0.001; benzo(g,h,i)perylene, 0.1;
chrysene, 0.1; acenaphthene, 0.001; acenaphthylene, 0.001; ﬂuoranthene, 0.01; ﬂuorene, 0.001; naphthalene, 0.001; phenanthrene, 0.001; pyrene, 0.001]. dForestomach papillomas and car-
cinomas. eAlveolar and bronchial adenomas and carcinomas. fAt these doses, all tumor-bearing animals died before the end of the 2-year exposure period.factors for BaP was previously discussed in the
use of a preliminary BMD method to derive a
guideline value for BaP (Fitzgerald 1998). The
modifying factor of 6,000 is slightly altered
here in light of the additional data obtained
from the recent studies by Culp et al. (1998).
BaP exhibits high lipophilicity and is
metabolized in all tissues studied, and its
metabolites are potent gene and chromosome
mutagens, suggesting that the response of
humans to BaP is likely to be more similar to
that of mice than a maximum (default) inter-
species extrapolation factor of 10 would imply
(i.e., there is no evidence indicating that
humans could be 10 times more sensitive than
mice to BaP carcinogenicity). Several in vitro
studies of BaP metabolism, mutagenicity, and
DNA adduct formation using human and ani-
mal cells or tissue components suggest that BaP
is not more toxicologically active in human
cells than in mouse cells (Hengstler et al. 1999;
Hsu et al. 1987; Oesch et al. 1977; Roggeband
et al. 1993). However, an exception to this is
seen with comparative studies of mammary
cells exposed to BaP (Hengstler et al. 1999).
Given this, and the limitations of extrapolating
from in vitro data, we propose a modifying fac-
tor of 5 for interspecies extrapolation.
The intraspecies variability factor is set at
10 because of the lack of human data available.
The adequacy of database factor, whereby the
better the quality of the relevant tumor studies
the smaller the factor, is given a value of 2 to
reﬂect a high degree of conﬁdence. The study
of Culp et al. (1998) extended over the lifetime
of the animals and included a suitable number
of dose levels. The malignancy of BaP in a
range of tissues is well established and—
together with the Culp et al. (1998) bioassay
study in which BaP induced tumors in the
esophagus, tongue, larynx, and forestomach—
engenders a proposed modifying factor of 9.
The maximum factor of 5 for genotoxicity was
assigned because this property of BaP is well
established and BaP is a potent mutagen.
Thus, the overall modifying factor is
5 × 10 × 2 × 9 × 5 = 4,500.
Results
BaP. The fitting of forestomach tumor
dose–response curves to the the BaP data of
Culp et al. (1998) (Table 1) is shown in
Figure 1. Figure 1A depicts the plotted models
relative to the Culp et al. BaP data, and
Figure 1B shows the extra risk–dose curves
derived from them. The calculated value of
0.362 mg/kg/day for BMD0.05, as shown in
the Supplemental Material (http://ehp.niehs.
nih.gov/members/2004/6427/supplemental.
pdf), is an average from six of the models. The
excluded model is the truncated normal model
because it could not be ﬁtted to the data. This
lack of ﬁt occurs when the curves are “supra-
linear” or nearly so, as is the case here. This
may also occur with some data sets for the
truncated logistic model.
Development of a soil BaP guideline
value from the BMD0.05. Taking the BaP
BMD0.05 of 0.362 mg/kg/day and applying
the modifying factor of 4,500 yields the fol-
lowing guideline dose:
(0.362 mg/kg/day) ÷ 4,500 = 0.08 µg/kg/day.
This yields the following maximum daily
intakes (MDI) for adults (assuming 70 kg
body weight) and children (assuming 13.2 kg
for a 2-year-old child): 
0.08 µg/kg/day × 70 kg = 5.6 µg/day 
for an adult,
0.08 µg/kg/day × 13.2 kg = 1.06 µg/day 
for a child.
These MDIs represent the total daily BaP
intake that should not be exceeded in order to
safeguard human health. Some of this intake
is assumed to come from food; consequently,
the TDI from soil is calculated to be the MDI
minus the intake from food, divided by 2 for
a measure of safety and to allow for some
exposures via air and water (Fitzgerald 1998).
In a previous BaP guideline value calcula-
tion (Fitzgerald 1998), a U.S. EPA upper esti-
mate for BaP intake in food of 1.6 µg/day
(U.S. EPA 1980) and a U.K. estimate of a
child’s BaP intake being 40% of an adult’s
intake (RPS 1995) were used. If we used these
same values, the allowable daily intake for BaP
from soil would be (5.6 – 1.6) ÷ 2 = 2.0 µg for
adults and (1.06 – 0.64) ÷ 2 = 0.21 µg for
children. Based on an assumed adult soil
ingestion rate of 25 mg/day [Australia and
New Zealand Environment Conservation
Council (ANZECC) and NHMRC 1992], a
BaP soil guideline value would be
2.0 µg BaP ÷ 25 mg soil = 80 ppm.
For children, an assumed soil ingestion rate is
100 mg/day (ANZECC and NHMRC 1992);
thus, a BaP soil guideline value would be
0.21 µg BaP ÷ 100 mg soil = 2.1 ppm.
One of the key data sets in this approach is the
estimate for daily dietary BaP intake. Better
estimates for intake than those used above may
be obtained from recent data from a U.S. study
of 200 food items and 228 subjects (Kazerouni
et al. 2001), which indicated that all adults in
the study consumed < 0.16 µg BaP/day.
Applying this to the above method, the allow-
able daily BaP intake from soil would be
(5.6 – 0.16) ÷ 2 = 2.72 µg for adults and
(1.06 – 0.06) ÷ 2 = 0.50 µg for children.
Further, a BaP soil guideline based on adult
soil ingestion would be
2.72 µg BaP ÷ 25 mg soil = 108 ppm.
For children, the calculation would be
0.50 µg BaP ÷ 100 mg soil = 5.0 ppm.
As previously suggested (Fitzgerald 1998), the
least value of such calculations is proposed as
the BaP soil guideline value, in this case,
5 ppm.
Coal tar mixtures. Using the coal tar
doses from the cancer bioassay study of Culp
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Figure 1. Suite of models ﬁtted to BaP dose–response data (mouse forestomach tumors) reported by Culp
et al. (1998). (A) MLE ﬁtting of models except the truncated normal, which could not be ﬁtted. (B) The extra-risk
dose curves of (A) in the low-dose region around the 0.05 risk level and averaged dose at 0.362 mg/kg/day.
Table 2. Modifying factors for BaP.a
Range BaP
Factor of value value
Interspecies extrapolation ≤ 1–10 5
Intraspecies variability 1–10 10
Database adequacy 1–2 (high) 2
3–7 (medium)
8–10 (low)
Malignancy 3–10 9
Genotoxicity 1–5 5
Overall factor 4,500
aSee NHMRC (1999) and Fitzgerald (1998).et al. (1998) (Table 1) to develop a guideline
value is complicated by numerous factors.
There is insufficient toxicologic information
available on coal tar mixtures to confidently
establish defensible modifying factors. In addi-
tion, there are no published MDI values for
coal tar (or PAH) mixtures and no figures
available on average coal tar (or PAH) intake
from diet. Even if these ﬁgures were available,
mixtures of coal tars and their bioavailability
differ according to their source, the soil type,
and degree of “aging” in the environment
(Abdel-Rahman et al. 2002; Bordelon et al.
2000; Reeves et al. 2001). Consequently, any
guideline value developed from cancer bio-
assay data on a particular coal tar mixture may
not apply to subsequently encountered coal tar
mixtures.
Instead, a pragmatic approach commonly
taken with PAH mixtures is to calculate the
BaP equivalence dose, based on TEFs with
BaP as the reference carcinogen (Boström et al.
2002; Fitzgerald 1998). For the present coal tar
mixtures, this addition of BaP equivalents
using previously proposed equivalence factors
(Fitzgerald 1998) resulted in BaP equivalence
doses approximately twice the actual BaP con-
centrations (Table 1). These calculations
showed < 30% variance from BaP equivalence
doses generated by two other TEF schemes
(Larsen and Larsen 1998; Nisbet and LaGoy
1992). Not previously considered for TEFs
were the naphthalene derivatives 1-methyl-
naphthalene and 2-methylnaphthalene, which
were prominent PAHs in the coal tar mixtures
(Culp et al. 1998). Available toxicity data were
limited, and TEFs of 0.001 were assigned to
both isomers.
The most sensitive tumorigenic response to
the coal tar mixtures was with lung tumors
(Culp et al. 1998). Preliminary modeling of
BaP equivalence doses and lung tumor data of
coal tar exposures (not shown) revealed non-
simple ﬁts and considerable variability between
the mixtures. Further detailed analysis is
beyond the scope of the present study.
Discussion
The present study represents the ﬁrst signiﬁ-
cant attempt to use the modified BMD
method as developed in Australia for generat-
ing guideline values for environmental car-
cinogens. The present program focuses on
BaP as the key surrogate for PAHs and builds
on preliminary work in this area (Fitzgerald
1998). With this approach, we propose a BaP
soil guideline value of 5 ppm. This would rep-
resent a signiﬁcant departure from the current
Australian soil guideline for BaP of 1 ppm that
was based on consideration of proportionality
of dietary BaP and related cancer risk derived
from U.S. EPA LMS modeling (Fitzgerald
1991; National Environment Protection
Council 1999).
In the absence of human data, the described
method has employed experimental animal
data. The BMD0.05 of 0.362 mg BaP/kg/day
we used is considered a refinement of the
0.815 mg BaP/kg/day BMD0.05 determined in
previous work, employing the MLE method
with quantal Weibull and polynomial regres-
sion modeling of earlier bioassays (Fitzgerald
1998; Neal and Rigdon 1967). Although Neal
and Rigdon’s data set was the best BaP tumor
dose response available at the time and
includes more groups in the low-dose region
than does the data set of Culp et al. (1998),
we consider it to be less suitable for BMD
development principally because of the less-
than-lifetime BaP exposures (3–6 months vs.
24 months).
Although the use of computer-based
modeling in guideline development is quite
sophisticated and reasonably defensible scien-
tifically, the component of guideline value
derivation that involves modifying factors is
probably the most subjective part of the entire
process. Nonetheless, such factors are used
routinely in regulatory toxicology and are
often termed uncertainty factors or safety fac-
tors. For some of these, for example, default
interspecies extrapolation and intraspecies
variability, there are empirical data to indicate
a fair degree of confidence that they are not
unreasonable although likely to be conserva-
tive (Dourson et al. 1996; Fitzgerald 1993;
Lewis et al. 1990). Where information exists
to allow a factor other than the default, for
example, comparative toxicokinetic data or, as
in the present case, a range of intuitive argu-
ments around interspecies BaP extrapolation,
a nondefault factor can be used.
For the “safety factor” portion of the
overall modifying factors, namely, database
adequacy, malignancy, and genotoxicity, judg-
ment is somewhat subjective. Nonetheless,
the suggested approach is based on interna-
tionally used assessment methods [NHMRC
1999; World Health Organization (WHO)
1994].
A further variable of the guideline value
equation that has a major bearing on the out-
come is the estimate of daily dietary BaP
intake. Recent data indicating that BaP intake
may be decreasing over time (Kazerouni et al.
2001; U.S. EPA 1980) could perhaps be
explained by the stricter emission controls on
industries that release PAHs; reduced PAHs in
air pollution would mean reduced deposition
on plants and reduced uptake by farm animals
(Kazerouni et al. 2001).
The final variable affecting the guideline
value generation is that of soil ingestion rate.
For the present study, we used daily rates of
25 mg for adults and 100 mg for children
because they are generally adopted by regula-
tory toxicologists in Australia (ANZECC and
NHMRC 1992). However, we recognize that
these values may be different in other countries
(Gargas et al. 2000), although the intake used
for children is similar to 95th percentile esti-
mates determined recently for children residing
near a U.S. Superfund site (Stanek and
Calabrese 2000).
Potentially the most significant aspect of
the data of Culp et al. (1998) is that concern-
ing tumor responses to dietary coal tar mix-
tures in which the tumor profile was quite
different from that with BaP, both qualita-
tively and quantitatively. Of particular note
was the ﬁnding that, purely in terms of con-
centration, the BaP in the mixtures could
explain the forestomach tumors induced by
the mixtures but could not explain the lung
tumors (Figure 2); BaP alone was a weak
inducer or noninducer of lung tumors at the
doses tested. Such preferential induction of
lung tumors in mice by a PAH mixture com-
pared with BaP has been previously reported
(Weyand et al. 1995).
Speculatively, one may propose either that
the action of BaP (or BaP equivalents) is syner-
gized in the mixture milieu in a way that selec-
tively induces lung tumors, or that some other
component of the mixture is tumorigenic in
the mouse lung. The latter notion, together
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Figure 2. Comparison of dose responses for tumors reported by Culp et al. (1998), plotted for BaP alone and
BaP content of coal tar mixtures. (A) Forestomach tumors. (B) Lung tumors.with indication of a non-BaP compound inter-
acting with lung DNA (Culp et al. 2000;
Goldstein et al. 1998; Weyand and Wu 1995),
has led to the ﬁnding that the causative agent
may be 7H-benzo(c)ﬂuorene (BcF) (Goldstein
2001; Koganti et al. 2000, 2001) and that
in vivo bioavailability and metabolism of this
PAH are probably much greater than for BaP
(Koganti et al. 2001). Recent evidence further
points to dihydrodiol and diol epoxide
metabolites of BcF as being the proximate and
ultimate carcinogenic moieties, respectively,
that bind to mouse lung DNA (Wang et al.
2002). Recent studies have also examined sepa-
rately the lung carcinogenicity of BcF (about
9 mg/kg/day) and equimolar BaP (about
10 mg/kg/day) given in the diet of lung-
tumor–susceptible female A/J mice over
260 days (Weyand EH, personal communica-
tion; Weyand et al. 2002). The data showed
that BcF increased the prevalence of mice with
lung tumors (from 77% for BaP to 100%) but,
most signiﬁcantly, increased the multiplicity of
lung tumors 33-fold (Weyand et al. 2002).
This suggests that for future PAH risk assess-
ments and setting of regulatory guidelines,
more consideration of BcF levels will be
needed, as well as some rethinking of the
prominence afforded BaP and associated TEFs
in current regulatory science (Goldstein 2001).
Culp et al. (1998) did not report on BcF levels
in the coal tar mixtures used in their studies.
A further possible consideration stems
from the notion that lung tumorigenesis ought
to be the cancer risk assessment driver for
ingested PAH mixtures. That is, because lung
tumorigenesis is the risk assessment driver for
air/PAH inhalation, then evaluation of soil
particle inhalation should be contemplated.
However, mitigating against this are recent
data suggesting that the deposition efﬁciency of
airborne soil particles in the tracheobronchial
and pulmonary regions of the lung is very low
(Khalili and Thomas 2001).
The BaP forestomach tumor data from
Culp et al. (1998) have been used to revise the
U.S. EPA LMS cancer slope factor for BaP
(Gaylor et al. 1998, 2000). Also, risk assessors
have proposed BaP soil guideline values using
TDI based on the LMS paradigm and “accept-
able” lifetime cancer risk estimates (Boyd et al.
1999). It is beyond the scope of this article to
examine such approaches. However, the pre-
sent BMD method is a departure from LMS
that does not operate on an assumption of low-
dose linearity or attempt any policy decision
on acceptable human population cancer risk.
Instead, it makes fuller use of all the tumor
dose–response data and is based on a more
realistic central estimate.
Conclusion
We have proposed a guideline value for BaP in
soil using a modiﬁed BMD method developed
within the Australian regulatory toxicology
community. As now required by the Australian
government health authorities, this work will
be extended to include other carcinogens that
exist in a range of environmental media.
Further work may also examine the general
validity of the safety factors employed and
whether scientiﬁc uncertainty around the 5%
extra risk starting point may be reduced.
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